Advertisement


Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial

2018 ASCO Annual Meeting

Advertisement

Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).



Related Videos

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial

Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (Abstract TPS4597).

Bladder Cancer

Toni K. Choueiri, MD, and Jonathan E. Rosenberg, MD: Bladder Cancer Roundup

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).

Lung Cancer
Immunotherapy

Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial

Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1% (Abstract LBA4).

Sarcoma

Gianni Bisogno, MD, on Rhabdomyosarcoma: Results From the European Paediatric Soft Tissue Sarcoma Study Group

Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2).

Head and Neck Cancer

Manisha H. Shah, MD, on Thyroid Cancer: Advances in Precision Medicine

Manisha H. Shah, MD, of The Ohio State University Comprehensive Cancer Center, summarizes a session she chaired on progress in tailored treatments for medullary and anaplastic thyroid cancers as well as salivary gland cancer.

Advertisement

Advertisement




Advertisement